Bulkamid® Urethral Bulking System is a minimally invasive surgical treatment for stress incontinence. Bulkamid is a biocompatible, non-absorbable urethral bulking agent that is injected under the mucosa to achieve better coaptation. Usually the procedure is performed under endoscopic inspection to ensure the correct placement of the bulking agent. The complete procedure requires about 15 to 20 minutes and may be performed on an outpatient basis.
Bulkamid® is composed of hydrogel that consists of 97.5% water and 2.5% cross-linked polyacrylamide. Hydrogel has special properties of exchanging the water with the surrounding tissues which helps the gel to resemble normal tissue. There are no solid particles in hydrogel which prevents any tissue hardening or impairment of urethral function.
Bulking agents are permanent synthetic materials which are non-allergic and non-scarring to the surrounded tissues. The material augments the sealing mechanism of the urethral wall and increases the resistance of the urinary bladder to control the urinary flow.
The procedure of Bulkamid® application is performed under general anaesthesia and endoscopic control. A urethroscope is gently pressed inside the channel to provide a clear view of the site of injection. The rotator sheath is retracted once the tip of the needle reaches the site of injection and the bulkamid is then injected into the submucosal tissues of the bladder neck.
Candidates for Bulkamid®
Urethral injection therapy using BULKAMID® may be an option for patients who are not suitable for a surgical procedure or for patients with residual incontinence that have already undergone other surgical repairs.
The contraindications of Bulkamid include patients with acute cystitis, urethritis or other autoimmune diseases. Patients who are receiving systemic corticosteroid treatment or who have a positive history of active herpes genitalis are also contraindicated for Bulkamid® treatment.